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ARTICLE
Antimalarial activity of primaquine operates
via a two-step biochemical relay
Grazia Camarda1, Piyaporn Jirawatcharadech1, Richard S. Priestley 1,7, Ahmed Saif1,8, Sandra March2,
Michael H.L. Wong 3, Suet Leung3, Alex B. Miller2, David A. Baker 4, Pietro Alano5, Mark J.I. Paine 6,
Sangeeta N. Bhatia2, Paul M. O’Neill3, Stephen A. Ward1 & Giancarlo A. Biagini 1
Primaquine (PQ) is an essential antimalarial drug but despite being developed over 70 years
ago, its mode of action is unclear. Here, we demonstrate that hydroxylated-PQ metabolites
(OH-PQm) are responsible for efﬁcacy against liver and sexual transmission stages of
Plasmodium falciparum. The antimalarial activity of PQ against liver stages depends on host
CYP2D6 status, whilst OH-PQm display direct, CYP2D6-independent, activity. PQ requires
hepatic metabolism to exert activity against gametocyte stages. OH-PQm exert modest
antimalarial efﬁcacy against parasite gametocytes; however, potency is enhanced ca.1000
fold in the presence of cytochrome P450 NADPH:oxidoreductase (CPR) from the liver and
bone marrow. Enhancement of OH-PQm efﬁcacy is due to the direct reduction of quino-
neimine metabolites by CPR with the concomitant and excessive generation of H2O2, leading
to parasite killing. This detailed understanding of the mechanism paves the way to rationally
re-designed 8-aminoquinolines with improved pharmacological proﬁles.
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S ince its development in the 1950s by the US Army, anestimated 200 million people have been administered PQ1.Research into the elusive PQ mode of action has mainly
focused on the identiﬁcation of the biochemical basis for its side
effect of hemolytic toxicity in patients with G6PD deﬁciency1.
Earlier studies led to the identiﬁcation of OH-PQm, generated
from hepatic phase I metabolism2, as potential culprits for
toxicity3,4. The most relevant species in this context include the
5-hydroxy (5-HPQ) and 5,6-dihydroxy (5,6-DPQ) primaquine
metabolites (Fig. 1a). These species are unstable, undergoing
spontaneous oxidation and producing the corresponding quino-
neimine forms (Fig. 1a, PQQI, 5-quinoneimine, and 6OHPQQI,
6-hydroxy-5-quinoneimine) with concomitant generation of
H2O25; quinoneimine metabolites can then be reduced back to
the hydroxylated form, leading to H2O2 accumulation. However,
their reduction potential is likely to be very negative, limiting the
pool of possible intracellular reductants with a sufﬁciently low
reduction potential to donate electrons. In proof-of-concept
studies using the strong reducing enzyme, ferredoxin-NADP
reductase (FNR) from spinach (note the Em,7 known for
the ferredoxin oxidised/reduced couple is ca. −430 mV), PQ
quinoneimines were shown to be enzymatically reduced5—but
despite intensive research efforts the exact enzyme(s) and meta-
bolic pathway(s) involved in the process remain to be fully
elucidated.
Similarly, the mechanism of action of primaquine against the
malaria parasite is also largely unknown6,7. A link between drug
efﬁcacy and metabolism through CYP2D6 is supported by recent
animal and clinical studies, including the association of CYP2D6
poor metaboliser phenotype status with primaquine failure in
controlled human malaria infections with P. vivax2,8. The need
for CYP2D6 metabolism to generate key OH-PQm9,10 supports
the assumption that these metabolites contribute to drug efﬁcacy;
however, hitherto there has been no direct demonstration of the
link between these metabolites and anti-parasitic activity. Any
explanation of PQ action needs to address the exquisite selectivity
against dormant and active liver stage parasites and the ability of
very low drug doses and subsequent low systemic exposures to
kill gametocyte stages of P. falciparum clinically11. This study
attempts to reconcile these questions.
Here OH-PQm in their hydroxyquinoline or quinoneimine
form have been synthesised and assessed for their activity against
P. falciparum gametocytes and liver stages. By assessing parasite
viability in the presence or absence of metabolic conversion we
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Fig. 1 Structures of PQ and OH-PQm and their activity against P. falciparum liver stages and gametocytes. a Structures of compounds used in this study.
b, f Dose dependent reduction in exoerythrocytic forms (EEFs) numbers at day 3.5 post infection with NF54 sporozoites in YEM (poor metaboliser, black
line) and NON (extensive metaboliser, dashed blue line) hepatocyte lots. b Primaquine (PQ). c 5-hydroxy-primaquine (5-HPQ). d 5-quinoneimine (PQQI).
e 5,6-dihydroxy-primaquine (5,6-DPQ). f 6-hydroxy-5-quinoneimine (6OHPQQI). Viability is expressed as mean percentage of vehicle control ± S.D.
of two independent experiments performed in triplicates. For each drug, IC50 values are reported for the poor metaboliser, YEM, and extensive metaboliser,
NON, hepatocyte lots. g Coupled in vitro metabolism-GC-LUC assay. PQ and PQ metabolites (30 μM) were reacted with (blue squares) or without
(red circles human liver microsomes (HLM) prior to dilution to 10 μM (nominal parental compound concentration) in a GC-LUC assay with mature
gametocytes. Viability was measured after 72 h and expressed as mean percentage of control (no drug) viability ± S.D. (n= 3, each in triplicate). h as in
g, but with (blue squares) or without (red circles) CYP2D6 (n= 2, 5 total replicates). For paroxetine inhibition, CYP2D6 was pre-incubated with 10 μM
paroxetine for 15 min prior to compounds (black triangles, n= 2, 4 total replicates); i as in g, but without (red circles) or with (blue squares) recombinant
human CPR, or with huCPR in the presence of 10mM sodium pyruvate (brown diamonds) with huCPR in the absence of NAPD+ (black triangles). NoNADP
+ n= 1 in duplicate; all other huCPR conditions n= 4 in duplicate
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show that OH-PQm full cidal potential requires further enzy-
matic catalysis. We identify the CYP2D6 redox partner, cyto-
chrome P450 NADPH:oxidoreductase (CPR), as required for
OH-PQm to exert full gametocytocidal activity, independently of
CYP2D6 status. We also show that OH-PQm activity against
P. falciparum liver stage development is comparable or better
than PQ and conﬁrm a dispensable role for CYP2D6 activity.
Finally, we substantiate the critical role of H2O2 production in
anti-parasitic activity and propose a CPR-mediated biochemical
model to account for PQ and OH-PQm mechanism of action.
These data answer long-held questions of why PQ displays
parasite stage-speciﬁc activity and why PQ displays transmission
blocking activity at such low doses.
Results
Inﬂuence of CYP2D6 on PQ antimalarial liver-stage activity.
To explore the activity of PQ and OH-PQm against P. falciparum
liver stage development, we used an advanced in vitro model that
consistently mimics liver physiology and supports complete
maturation of P. falciparum extra-erythrocyte forms (EEFs) in
the liver12. In this in vitro system, human primary hepatocytes
are organised into colonies surrounded by supportive stromal
cells (Micropatterned coculture, MPCC) and infected with
P. falciparum (NF54 strain) sporozoites12. To evaluate the role of
CYP2D6 in PQ and OH-PQm activity, we selected two hepato-
cyte lots, NON and YEM. YEM is a low metaboliser based on
genotype analysis, it has a variation in the CYP2D6 allele (*4/*4);
this was conﬁrmed by incubation with the CYP2D6 probe deb-
risoquine13 and measuring the metabolite 4-hydroxidebrisoquine
by mass spectrometry (MS) (Supplementary Fig. 1), conﬁrming
that the NON hepatocyte lot had twofold higher CYP2D6 activity
than the YEM lot.
OH-PQm were synthesised and used alongside PQ to directly
assess the inhibition of EEFs development in dose-response
experiments in the two hepatocyte lots. As shown in Fig. 1b, PQ
activity against EEFs development strictly depended on hepato-
cyte CYP2D6 status, with >14-fold increase in the IC50 measured
in the YEM background (low metaboliser, PQ IC50 5.87 μM) as
compared to NON hepatocytes (extensive metaboliser PQ IC50
0.40 μM). Conversely, all OH-PQm showed comparable IC50
values in the two hepatocyte lots (Fig. 1c–f), indicating that they
act independently of CYP2D6 activity. It is interesting to note
that all OH-PQm show similar potency against liver stages,
comparable to that seen for PQ in the presence of extensive
metaboliser hepatocytes. Taken together these results conﬁrm
that OH-PQm have direct killing activity against liver stages,
supporting the hypothesis that they act downstream of CY2D6
activity.
PQ gametocytocidal activity requires hepatic metabolism.
We next explored the anti-gametocyte activity of OH-PQm
and parental PQ through coupled in vitro metabolism-
gametocytocidal assays. In these assays, we ﬁrst incubated PQ
and OH-PQm with human liver microsomes (HLM) to mimic
bioactivation and then tested for gametocytocidal activity against
a P. falciparum 3D7A transgenic strain, expressing luciferase
speciﬁcally in the gametocyte stages14, in an improved gameto-
cyte viability assay GC-LUC (gametocyte luciferase)14. As shown
in Fig. 1g, PQ at 10 μM, as expected, has minimal activity in the
absence of any metabolic conversion (red histograms, (−)HLM).
When gametocytes were treated with OH-PQm, we observed little
to moderate gametocytocidal activity, with only demethoxylated
species, 5,6-DPQ and 6OHPQQI, able to reduce gametocyte
viability to less than 50 % of solvent control (Fig. 1g, (−)HLM).
After HLM metabolism (Fig. 1g, blue histograms, (+)HLM), PQ
gametocytocidal activity signiﬁcantly increased, conﬁrming that
metabolic transformation is also required for gametocyte killing
activity. Interestingly, a signiﬁcant increase in potency was also
observed for all OH-PQm after microsomal incubation (p value <
0.001 for all pairs by Mann Whitney test, Supplementary
Table 1). In both the presence and absence of metabolic con-
version, 5,6-DPQ showed the highest gametocytocidal potency
(Supplementary Table 2). These results conﬁrm that PQ requires
metabolic activation to elicit activity against both liver stage
parasites and gametocytes; gametocytocidal activity of OH-PQm
in the in vitro gametocyte setting is also shown to be HLM
metabolism-dependent.
To gain further insight, we directly assessed the role of
CYP2D6 in OH-PQm activity against gametocytes by performing
coupled in vitro metabolism-GC-LUC assays using CYP2D6-
expressing baculosomes (Fig. 1h). As with HLM, CYP2D6
treatment potentiated OH-PQm gametocytocidal activity, with
p < 0.05 for 5,6-DPQ and 6OHPQQI, and p < 0.001 for all other
compounds (Mann Whitney, Supplementary Table 3). However,
OH-PQm are believed to be the terminal products of primaquine
metabolism, so we further investigated these results by blocking
CYP2D6 activity with the speciﬁc inhibitor paroxetine15
(Supplementary Fig. 2) prior to drug in vitro metabolism and
GC-LUC assays. Interestingly, CYP2D6 inhibition did not
signiﬁcantly affect OH-PQm gametocytocidal activity (Fig. 1h,
compare (+)2D6 and (+)2D6+ Paroxetine); conversely, PQ
activity decreased (p < 0.05) as expected, reverting towards the
levels observed in control samples without CYP2D6 (Mann
Whitney, Supplementary Table 4). Overall, these results show
that OH-PQm activity is greatly enhanced by baculosome
metabolic component(s), however, the observed potentiation is
independent of CYP2D6 activity.
These results prompted us to hypothesise that OH-PQm might
be direct substrates of CPR, the CYPs redox partner required for
electron transfer from NAPDH16, an intrinsic (and required)
component of HLM and CYP2D6 baculosome preparations. We
therefore measured initial reaction rates of human recombinant
CPR (huCPR)17 with PQ and OH-PQm (Supplementary Fig. 5)
and generated the apparent steady-state kinetics for each
compound (Supplementary Table 5). These analyses revealed
that OH-PQm are indeed CPR substrates; conversely, kinetic
parameters showed parental PQ to be a poor CPR substrate, as
predictable from its structure, and hence it was not included in
the subsequent analysis. We then tested the gametocytocidal
ability of OH-PQm following incubation with huCPR and
observed that, akin to HLM and the baculosome treatment, in
the presence of huCPR only, the gametocytocidal activity of all
metabolites was signiﬁcantly increased (Fig. 1i, p < 0.001 for all
compounds, Mann Whitney, Supplementary Table 6). This effect
was completely prevented when the assay was performed in the
absence of NADP+, required for the production of the essential
cofactor NADPH by the reaction components (see “Methods”)
(Fig. 1i, compare (+)huCPR and (+)huCPR-No NADP+),
conﬁrming that huCPR catalysis mediates OH-PQm gametocy-
tocidal activity. Cognisant of the putative role of H2O2-producing
redox-active PQ metabolites in PQ haemolytic toxicity in
G6PDH-deﬁcient individuals3,18, we indirectly assessed the
contribution of reactive oxygen species to the gametocytocidal
activity of huCPR-treated PQ metabolites by using sodium
pyruvate as a H2O2 scavenger19. As shown in Fig. 1i (compare
huCPR and huCPR+ pyruvate), the presence of pyruvate
abrogated OH-PQm gametocytocidal activity (p < 0.01; Mann
Whitney, Supplementary Table 7). These results establish the
need for huCPR catalytic activity for OH-PQm mechanism of
action and point to a direct role for huCPR as a redox cycler of
OH-PQm.
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Redox cycling of PQ metabolites generates gametocytocidal
H2O2. To further conﬁrm this observation, we directly measured
H2O2 generation during drug incubation with human CPR
(huCPR). To this end, O2 consumption during incubations was
recorded using a closed O2 electrode and H2O2 was quantiﬁed via
oxygen release after catalase addition. As shown in Fig. 2a, all
metabolites, compared to methanol control, elicited H2O2 pro-
duction, whereas negligible amounts of H2O2 were detected when
PQ was used as a substrate. When sodium pyruvate was added to
CPR reactions, H2O2 production was completely abolished
(Fig. 2b). In addition, we measured H2O2 production in titration
experiments with 5-HPQ as a representative OH-PQm (Supple-
mentary Fig. 5) and observed that as low as 1 nM 5-HPQ is able
to elicit H2O2 production. We conﬁrmed H2O2 involvement in
gametocyte killing by directly assessing its production upon HLM
and CYP2D6 metabolism of PQ and 5-HPQ and 5,6-DPQ as
representative metabolites (Fig. 2c, d and Supplementary Fig. 4
for representative full traces of oxygen content). Collectively,
these data clearly demonstrate that huCPR is required for
OH-PQm anti-gametocyte activity and that this process occurs
through generation of H2O2, implying a redox cycling, CPR-
mediated mechanism of parasite death directly attributable to the
generation of H2O2.
H2O2 production by PQ in bone marrow. We reasoned that
spatial co-localisation of parasite and host-dependent metabolic
activating system(s) could account for PQ stage-speciﬁcity. For
EEFs this association is obvious with parasite residency within the
hepatocyte; for gametocytes this is less obvious as circulating
gametocytes are rarely in juxtaposition to a potential source of
metabolism. However, P. vivax and P. falciparum gametocytes,
including mature stages20,21, are sequestered/enriched in the bone
marrow22,23, which is also endowed with signiﬁcant P450-
dependent metabolic capacity24–26. To address this possibility,
the ability of PQ and OH-PQm to generate H2O2 in mouse bone
marrow cell extracts was investigated. Results in Fig. 2e show that
PQ and OH-PQm generated H2O2 when incubated with
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bone marrow crude cell extracts, whereas no H2O2 could be
detected with equivalent amount of proteins from red blood cells
(to represent the circulating parasite environment) (Fig. 2f).
These results support the view that localised H2O2 generation at
speciﬁc anatomical sites is responsible for stage-speciﬁc parasite
killing by PQ metabolites.
PQ-metabolite efﬁcacy at pharmacologically-relevant doses.
Next, we determined gametocyte inhibition sensitivity proﬁles
(IC50) of OH-PQm. Dose-response huCPR reactions were per-
formed prior to GC-LUC assays. As shown in Fig. 3, OH-PQm
are all active at pharmacologically-relevant nanomolar con-
centrations, with 5,6-DPQ being the most active with an IC50 of
15 ± 0.4 nM. Conversely, parental PQ shows an IC50 of 2.59 ±
0.77 μM, in strong agreement with the measured enzyme kinetics.
These results support a catalytic mechanism of action for PQ
metabolites via CPR-mediated redox cycling that is in line with
expected drug metabolite exposure after clinically relevant PQ
doses27–29.
Discussion
Our results unveil a two-step biochemical relay underlying PQ
mode of action relying on CYP2D6 and its redox partner CPR
(Fig. 4). PQ oxidation principally by CYP2D6 generates hydroxyl-
metabolites whose oxidation to quinoneimine generates H2O2.
Quinoneimines in turn are substrates for CPR reducing activity,
thus leading to H2O2 accumulation which can exert anti-parasitic
activity directly through oxidation of protein sulphydryl groups
and damage of Fe- and FeS-containing proteins or through the
generation of superoxide and hydroxyl radicals. The intrinsic
instability of parent hydroxyl-metabolites prevents identiﬁcation
of all the relevant chemical species in the process. However, it is
important to emphasise that our results show that quinoneimine
metabolites, considered as stable degradation products or markers
for the unstable hydroxylated forms28,29, are also substrates for
redox cycling activities involved in anti-parasitic action. Direct
demonstration of CYP2D6-dependent PQ antimalarial activity
against P. falciparum liver stages supports clinically-led hypoth-
eses for the essentiality of CYP2D6 for PQ activity8.
Signiﬁcantly, our data also shows that OH-PQm exert anti-
malarial activity against liver parasite stages independently of
CYP2D6 (Fig. 2). This ﬁnding has signiﬁcant implications for the
design of improved 8-aminoquinolines which retain antimalarial
activity but which importantly would not be determinately
affected by the CYP2D6 status of the patient.
The described biochemical relay accounts for a unique mode of
action (MoA) involving two host enzymes and has implications
not only for bioactivation but also for pharmacodynamics.
The elucidation of a catalytic (e.g. 1 nM) MoA for OH-PQm
(generating μM levels of H2O2, Supplementary Fig. 5) explains
how single low-dose PQ, down to 0.25 mg/kg, retains transmis-
sion blocking ability in clinical settings30; importantly, this
treatment is also well tolerated in G6PD deﬁcient patients30. The
emphasis on a host-mediated MoA, not directly involving any
parasite targets that are subject to selective pressure, may also
provide an explanation for the apparent lack of resistance to PQ
in the ﬁeld; in fact, treatment failure so far has only been linked to
CYP2D6 polymorphisms.
These results do not exclude a role for other human host strong
reducing enzymes in mediating PQ antimalarial activity. How-
ever, we propose that the tissue-speciﬁc juxtaposition of CYP2D6
and CPR, in the liver and bone marrow24–26, exquisitely explains
the susceptibility of liver stages, including hypnozoites, of
P. falciparum gametocytes, and of P. vivax gametocytes and
asexual stages, the latter recently shown to be enriched in the
bone marrow23. Moreover, the results presented accurately mir-
ror the clinical efﬁcacy data in that PQ appears to be more active
against gametocytes than liver stages. This observation supports
the validity of the in vitro models used here as proxies for in vivo
conditions.
Overall, these data provide a framework that will make it
possible to test the potential of rationally re-designing PQ ana-
logues that can be activated even against a backdrop of CYP2D6
poor metaboliser status. Furthermore, armed with this knowl-
edge, it will be possible to test if antimalarial activity can ever be
divorced from haemotoxicity.
Methods
Reagents. All chemical reagents were from Sigma-Aldrich unless otherwise
speciﬁed.
Chemical syntheses. Reactions that were air and moisture sensitive were per-
formed under a nitrogen or argon atmosphere. This was achieved with oven dried
or ﬂame dried glassware sealed with a rubber septum. Dry nitrogen gas was
introduced via a manifold or balloon.
Reactions were stirred using Teﬂon-coated magnetic stir bars. Organic solutions
were concentrated using a Büchi rotary evaporator with a diaphragm vacuum
pump. Anhydrous solutions and sensitive liquids were transferred via syringe.
All reagents were purchased from Sigma Aldrich or Alfa Aesar and were used
without puriﬁcation unless otherwise indicated. 5,6-dimethoxy-8-nitroquinoline
was obtained from WuXi AppTec.
1H NMR spectra were measured on a Brucker AMX400 (400MHz) nuclear
magnetic resonance spectrometer. Solvents are indicated in the text. The data for
1H NMR spectra are reported as follows: chemical shifts were described in parts per
million (δ, ppm) downwards from an internal reference of trimethylsilane. 13C
NMR spectra were measured on a Brucker AMX400 (100MHz) and are reported
in terms of chemical shift (δ, ppm) relative to residual solvent peak. MS and High
resolution mass spectrometry (HRMS) were recorded on a VG analytical 7070E
machine, Frisons TRIO spectrometers or Agilent QTOF 7200 using chemical
ionisation (CI) or electron ionisation (EI). Micromass LCT mass spectrometer used
electron spray ionisation (ESI).
The synthesis of metabolites was based on modiﬁcations of literature
procedures (Supplementary Fig. 6)31,32 as described below.
For the synthesis of 5,6-dimethoxyquinolin-8-amine31 5,6-dimethoxy-8-
nitroquinoline (2 g, 8.54 mmol) was dissolved in Tetrahydrofuran (THF, 20 mL). A
solution of sodium hypophosphite (6 g, 68.32 mmol) in 10 mL water was added to
the reaction. The ﬂask was purged with nitrogen. 10% palladium on carbon (0.7 g)
was added to the reaction mixture and purged with nitrogen. The reaction was
allowed to stir vigorously for 10 min. A celite pad was prepared and the reaction
mixture was ﬁltered through the pad of celite and washed through with 20 mL
100
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Fig. 3 Dose-response viability of late stage gametocytes treated with
PQ and OH-PQm upon reaction with human CPR. Compounds at
concentrations ranging from 30 μM to 11.7 nM were incubated with human
CPR and diluted 1:3 for GC-LUC assays (n= 2, each in triplicate). IC50s
(±S.E.M.) were calculated from nonlinear regression (curve ﬁt) in
GraphPad Prism
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chloroform. Sodium hydroxide (2 M, 50 mL) was added to the ﬁltrate. The ﬁltrate
was extracted with chloroform (3 × 100 mL) and the combined organic extracts
were washed with water (2 × 50 mL), dried over magnesium sulphate and ﬁltered.
The chloroform was removed under reduced pressure to obtain the pure product
(1.72 g, 98.5%) as a red-orange solid; Rf= 0.15, 30 % ethyl acetate in hexane; 1H
NMR (400MHz, CDCl3) δ 8.62 (dd, J= 4.1, 1.6 Hz, 1 H), 8.33 (dd, J= 8.5, 1.6 Hz,
1 H), 7.35 (dd, J= 8.5, 4.1 Hz, 1 H), 6.73 (s, 1 H), 4.87 (s, 2 H), 3.96 (s, 3 H) and
3.89 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 149.6, 145.6, 141.5, 133.8, 133.2, 129.9,
124.5, 121.6, 99.1, 61.6 and 56.8; IR νmax (neat)/cm−1 3443, 3337 (NH), 3192 (CH)
and 1623 (C=C); HRMS calculated for C11H12N2O2 [M+H]+ 205.0972 found
205.0977.
For the synthesis of 4-bromo-1-phthalimidopentane, potassium phthalimide
(10 g, 53.99 mmol) was dissolved in acetone. 1,4-Dibromopentane (9.57 mL,
70.19 mmol) was added to the mixture which was heated to reﬂux for 24 h. The
reaction was cooled and ﬁltered. The acetone was removed under reduced pressure
and the crude product was puriﬁed via ﬂash chromatography resulting in (14.62 g
91%) a clear light yellow oil. Rf= 0.43, 20% ethyl acetate in hexane; 1H NMR (400
MHz, CDCl3) δ 7.88–7.81 (m, 2 H), 7.76–7.70 (m, 2 H), 4.22–4.10 (m, 1 H), 3.72
(dd, J= 8.5, 4.7 Hz, 2 H), 2.02–1.74 (m, 4 H) and 1.70 (d, J= 6.7 Hz, 3 H); 13C
NMR (100MHz, CDCl3) δ 168.4, 134.1, 132.1, 123.3, 50.6, 38.1, 37.2, 27.1 and
26.5; HRMS Calculated for C13H14BrNO2 [M+H]+ 296.0281 found 296.0280.
5,6-Dimethoxy-8-aminoquinoline (500 mg, 2.45 mmol) was added to a dry 50 mL
two neck ﬂask along with a dry magnetic bar. A dry condenser and equilibrating
dropping funnel were attached to the ﬂask and the second neck was sealed with a
rubber septum. The system was purged with dry argon and sealed with a balloon
attached to the dropping funnel. 1-Phthalimido-4-bromopentane (942.6 mg, 3.18
mmol) was added directly to the reaction via syringe and the reaction was then
heated to 150 °C to produce a dark paste. Triethylamine (444 µL, 3.18 mmol)
was added to the reaction via the dropping funnel over a 1.5 h period. The reaction
was left to stir for a further 1.5 h. Additional 1-phthalimido-4-bromopentane
(1.23 g, 4.16 mmol) was added directly to the reaction via syringe. Triethylamine
(290.3 µL, 2.08 mmol) was added to the reaction via the dropping funnel over
30 min. The reaction was left to stir for a further 2 h. 1-Phthalimido-4-
bromopentane (235.7 mg, 795.7 µmol) was added to the reaction directly via
syringe. Triethylamine (122.9 µL, 881.4 µmol) was added to the reaction via the
dropping funnel over 30 min. The reaction was left to stir for a further 2 h and
monitored by thin layer chromatography (TLC). The reaction was cooled, diluted
with acetone and ﬁltered. The acetone was removed, resulting in a dark oil which
was dissolved in chloroform (100 mL). The organic layer was washed with water
(3 × 50 mL), dried over magnesium sulphate and ﬁltered. The crude product was
pre-absorbed onto silica and puriﬁed via ﬂash chromatography to obtain the
product (790.5 mg, 77%) as a yellow oil; Rf= 0.3, 30% Ethyl Acetate in Hexane; 1H
NMR (400MHz, CDCl3) δ 8.53 (dd, J= 4.1, 1.6 Hz, 1 H), 8.27 (dd, J= 8.5, 1.6 Hz,
1 H), 7.84–7.78 (m, 2 H), 7.72–7.66 (m, 2 H), 7.33 (dd, J= 8.5, 4.1 Hz, 1 H), 6.41 (s,
1 H), 5.89 (d, J= 6.4 Hz, 1 H), 3.99 (s, 3 H), 3.86 (s, 3 H), 3.74 (t, J= 7.1 Hz, 2 H),
3.71–3.63 (m, 1 H), 1.99–1.62 (m, 4 H) and 1.30 (d, J= 6.3 Hz, 3 H); 13C NMR
(100MHz, CDCl3) δ 168.6, 150.0, 144.8, 141.9, 134.0, 133.7, 132.2, 131.3, 129.8,
124.6, 123.3, 121.7, 94.3, 61.6, 57.0, 48.1, 38.1, 34.1, 25.5 and 20.8; IR νmax (neat)/
cm−1 3390 (NH), 2964, 2936 (CH) and 1707 (C=O); HRMS Calculated for
C24H25N3O4 [M+H]+ 420.1923 found 420.1922.
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Fig. 4 Schematic representation of primaquine mode of action. The results presented in this work support a two-step biochemical relay mechanism for PQ
mode of action. In Step 1, PQ is converted into hydroxylated metabolites (OH-PQm) through the CPR/CYP2D6 metabolic complex. In Step 2, metabolites
then undergo spontaneous oxidation to quinoneimines (O= PQm) with concomitant generation of H2O2. Human CPR then receives two electrons from
NADPH and orchestrates one-electron transfers via FAD/FMN cofactors to quinoneinimes, thus reducing them back to the hydroxyl forms and
perpetuating a catalytic cycle which brings about H2O2 accumulation at sites of metabolic transformation (liver, bone marrow and possibly others).
Plasmodium parasites present at these locations are then killed by H2O2 action
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For the synthesis of 5,6 dimethoxy primaquine31, 5,6 dimethoxy-phthaloyl
primaquine (790.5 mg, 1.88 mmol) was dissolved in 25 ml of ethanol in a 50 mL
round bottom, a condenser was attached and the system was purged with nitrogen.
Sixty-ﬁve percent hydrazine monohydrate (465.5 µL, 6.22 mmol) was added to the
reaction and reﬂuxed (at 100 °C) for 6 h. A solid precipitate was observed. The
reaction was cooled and ﬁltered. The ethanol was removed and 30% potassium
hydroxide (100 mL) was added to the residue. The mixture was extracted with
diethyl ether (3 × 50 mL). The combined organic layers were washed with water
(50 mL), dried over magnesium sulphate and ﬁltered. A solution of 89%
phosphoric acid (187 µL, 2.73 mmol) in ethanol (5 mL) was added drop wise to the
ether solution. A red/orange precipitate was observed. The solvent was removed
under vacuo and the precipitate was recrystallised with ethanol to obtain an
orange/red solid (501 mg, 92%); 1H NMR (400MHz, DMSO) δ 8.57 (dd, J= 4.1,
1.5 Hz, 1 H), 8.23 (dd, J= 8.5, 1.5 Hz, 1 H), 7.47 (dd, J= 8.5, 4.1 Hz, 1 H), 6.55 (s,
1 H), 6.02 (s, 2 H), 3.94 (s, 3 H), 3.75 (s, 3 H), 3.80–3.71 (m, 1 H), 2.80 (t, J= 6.3
Hz, 2 H), 1.79 –1.55 (m, 4 H) and 1.23 (d, J= 6.2 Hz, 3 H); 13C NMR (100 MHz,
DMSO) δ 149.8, 144.6, 141.5, 132.6, 130.0, 129.2, 123.8, 122.0, 94.0, 60.9, 56.5, 46.9,
38.9, 33.1, 24.1 and 20.4; HRMS Calculated for C24H25N3O4 [M+H]+ 420.1923
found 420.1922.
Two general procedures were used for demethylation, as indicated. The general
procedure 1 was based on a modiﬁed procedure of Allahyari et al.32. Ten milligram
of 5,6 dimethoxy primaquine was dissolved in 1 mL of 48% hydrogen bromide
solution (ca 6M) and sealed under argon in a sealed tube. The reaction was heated
to 120 °C on a pre-heated mantle for 20 mins. Under a ﬂow of nitrogen, 5 mL of
water was added and the product(s) were puriﬁed via HPLC. For the general
procedure 2, 10 mg of 5,6 dimethoxy primaquine was dissolved in 1 mL of 48%
hydrogen bromide solution and the solution was allowed to stir for 6 h. Excess
reagent was removed under vacuum to give a brown solid that was stored under
nitrogen.
HPLC conditions were as follows: a Phenomenex Jupiter Proteo 90 A column,
250 × 10mm, 10 Micron was used for puriﬁcation using a gradient system based on
the following conditions; Initial (time 0) solvent mix 5% acetonitrile, 95% 0.05%
triﬂuoracetic acid (TFA) in water; 20mins, 25% acetonitrile, 75% 0.05% TFA in water;
20.10 min 5% acetonitrile, 95% 0.05% TFA in water; ﬂow rate was 5ml min−1.
All samples were dried by blowing off the solvent under a ﬂow of nitrogen 5,6-
dihydroxyprimaquine (5,6-DPQ) was prepared according to general procedure 2;
this compound was very unstable rapidly oxidising to 5-hydroxy quinoneimine
(5-HPQ) in solutions exposed to air. (MS for C14H19N3O2 [M+H]+ found
262.33). The metabolite was stored under nitrogen in a sealed tube.
For the synthesis of 5-hydroxy primaquine (5-HPQ) general procedure 1 along
with HPLC puriﬁcation and drying was used (see HPLC conditions above).
5-Hydroxy 6-Methoxy Primaquine= 10.06 min. The 5-hydroxy 6-methoxy
primaquine was very unstable as it readily oxidises to the quinoneimine form.
LCMS has shown that this is present within the reaction mixture, however, upon
isolation and re-evaluation using the HPLC conditions, the retention time at 10.06
min corresponding to the product is no longer observed. Once the quinoneimine
has formed from 5-OH primaquine, it is readily converted to the 6-hydroxy form
(6OHPQQI; Rt= 12.55 mins) by a demethylation reaction (through reaction with
water).
For the synthesis of Primaquine quinone-imine (PQQI), general procedure 1
provides the -hydroxy primaquine which can be allowed to oxidise to the
quinoneimine in aqueous solution. HPLC puriﬁcation and drying (see above) were
used for isolation. The quinoneimine was puriﬁed with two HPLC puriﬁcation
runs. Retention time:= 7.76 min 1H NMR (500MHz, D2O) δ 9.03 (d, J= 3.6 Hz,
1 H), 8.59 (d, J= 6.6 Hz, 1 H), 7.96 (dd, J= 8.0, 4.8 Hz, 1 H), 6.99 (s, 1 H), 4.22 (s,
3 H), 3.07 (t, J= 7.6 Hz, 3 H), 2.11–1.95 (m, 3 H), 1.88–1.72 (m, 3 H) and 1.58 (d,
J= 6.5 Hz, 3 H); MS for C15H19N3O2 [M+H]+ found 274.38.
For the synthesis of 6-hydroxy primaquine quinone imine (6OHPQQI), general
procedure 2 along with HPLC puriﬁcation and drying (see section 1.1.3) was used.
This compound could also be produced by reaction of the 6-methoxy
quinoneimine in aqueous solution followed by HPLC puriﬁcation. (See analysis
below) Retention time:= 12.55 min. 1H NMR (500MHz, D2O) δ 8.86 (dd, J= 4.9,
1.7 Hz, 1 H), 8.40 (dd, J= 7.9, 1.7 Hz, 1 H), 7.75 (dd, J= 7.9, 4.9 Hz, 1 H), 6.12 (s, 1
H), 4.11 (dd, J= 13.1, 6.7 Hz, 1 H), 3.05 (t, J= 7.4 Hz, 2 H), 1.92–1.74 (m, 4 H) and
1.42 (d, J= 6.5 Hz, 3 H); MS for C14H17N3O2 [M+H]+ found 260.35.
In vitro metabolism and redox cycling reactions. Human liver microsomes
(HLM, BD Biosciences) and CYP2D6-expressing baculosomes from the Vivid
CYP450 kit (Life Technologies) were used for compound metabolic conversions as
per manufacturer’s instructions with minor modiﬁcations. For HLM, compounds
(30 μM ﬁnal concentration) were incubated in the presence of NAPDH Regen-
eration System Solution A and B (BD Biosciences) at 37 °C for 2 h in a total volume
of 100 μl of phosphate reaction buffer. For CYP2D6 baculosomes reaction, a 2×
master mix (50 μl) was prepared containing reaction buffer, baculosomes, regen-
eration system and NADP+ (all from Life technologies). Compounds (30 μM ﬁnal
concentration) were prepared in 40 μl reaction buffer containing NADP+ as per kit
protocol. The total volume was brought to 100 μl with reaction buffer and reactions
incubated at 37 °C for 2 h. For CYP2D6 inhibition, we ﬁrst determined paroxetine
inhibitory proﬁle using Vivid CYP2D6 Blue kit (Life Technologies) according to
manufacturer’s instructions. For gametocytocidal assays, master mixes without
compounds were pre-incubated with paroxetine (10 μM) for 15 min at 37 °C before
addition of compounds and further incubation 37 °C for 2 h. Recombinant
huCPR17 was used for in vitro redox cycling of compounds. Reactions were per-
formed as described above with minor modiﬁcations. A master mix without
baculosomes was prepared as above; huCPR were added in 10 μl of reaction buffer
(200 nM ﬁnal concentration) and reactions started by adding 40 μl of compound/
NADP+ mix. For H2O2 scavenging, sodium pyruvate (10 mM) was used, without
pre-incubation. All experiments contained control reactions with solvent (MeOH:
water 50:50) only. After incubations, reaction mixes were spun down, supernatants
collected, diluted 2:3 and seeded into 96-well plates for GC-LUC assay.
Parasite culture, drug treatments and gametocyte luciferase assay (GC-LUC).
A P. falciparum 3D7A33 transgenic derivative 3D7elo1-pfs16-CBG99 was used14,34,
speciﬁcally expressing the CBG99 luciferase in gametocytes. Parasites were cul-
tured35 in human 0+ erythrocytes at 5% haematocrit under 5% CO2, 2% O2, 93%
N2. Cultures were grown in complete medium (CM) containing RPMI 1640
medium (Gibco) supplemented with 25 mM Hepes (VWR), 50 μg mL−1 hypox-
anthine, 0.25 mM NaHCO3, 50 μg mL−1 gentamicin sulfate, and 10% pooled heat
inactivated AB+ human serum. Gametocyte viability was evaluated by the GC-
LUC assay14,34. Parasites were quickly harvested in 2× CM before addition to
96-well plates containing control, CYP2D6- or huCPR-treated compounds (10 μM
parental compound ﬁnal concentration) in aqueous solution and incubatied at
37 °C for 72 h. Drug-treated gametocytes were then transferred to 96-well white
plate; D-Luciferin, 1 mM in 0.1 M citrate buffer pH 5.5 (Promega), was added in a
1:1 ratio and luminescence measurements were recorded after 10 min on a
FLUOstar Omega plate reader (BMG Labtech). Viability was expressed as % via-
bility as compared to solvent treated controls.
Liver stages assay. Micropatterned hepatocyte-ﬁbroblast co-cultures were
established as previously described12,36. Brieﬂy, soft lithography techniques were
used to pattern rat tail type I collagen (Corning) into 500 µm diameter islands on
the surface of glass bottom 96-well plates. Cryopreserved primary human hepa-
tocytes (Bioreclamation IVT) were thawed and pelleted through centrifugation at
100 g for 6 min, assessed for viability using trypan blue exclusion (70–90% viabi-
lity) and 10,000 hepatocytes were seeded onto the collagen islands in serum-free
DMEM (Dulbecco’s Modiﬁed Eagle’s medium) with 1% Penstrep. Two to three
hours later, cells were washed with DMEM containing 1% Penstrep, and media was
replaced with hepatocyte culture media. The following day, each well was infected
with 70,000 fresh P. falciparum sporozoites. Three hours later, cultures were
washed with DMEM containing 3% Penstrep and 0.1% Fungizone, and 7000 3T3
J2 mouse ﬁbroblasts were added to establish the co-culture. Drug was administered
during daily media changes for 3 days. The impact on hepatocyte infection was
measured by enumeration of exoerythrocytic forms on day 3.5 post infection,
through staining for PfHSP70 and visualisation with a Nikon Eclipse Ti ﬂuorescent
microscope.
Determination of oxygen consumption and H2O2 production. Oxygen con-
sumption and H2O2 production measurements were performed using the Oxy-
therm system and O2 View software package v.2.06 (Hansatech Instruments Ltd).
Compounds ability to generate hydrogen peroxide after in vitro metabolism or
huCPR reaction, in the presence of regeneration system or 100 μM NADPH as
indicated, was assessed indirectly by measuring catalase-mediated oxygen release.
Once the kinetic trace for oxygen concentration within the mixture had reached a
plateau for at least 3 min, catalase (from bovine liver, prepared in 50 mM potas-
sium phosphate buffer, pH 7.0; ﬁnal assay concentration 10 µg ml−1) was added
and data recorded for a further 6 min. Oxygen concentration was recorded as nmol
mL−1. To allow for easier comparison of individual traces, the x axis was adjusted
by deﬁning the addition of catalase as t= 0, and the corresponding y axis value
deﬁned as 0 nmol mL−1.
For bone marrow experiments, femurs were dissected from mice following
schedule 1 procedure. The schedule 1 procedure was undertaken with local (LSTM
and UoL Animal Welfare Ethics Review Boards) and national (Home Ofﬁce
licence) authorisation. Bone marrow cells were ﬂushed out with cold Ringer’s
solution pH 7.4 (125 mM NaCl, 1.5 mM CaCl2, 5 mM KCl, 0.8 mM Na2HPO4)
using 2 ml syringe connect with a 25GA needle. The bone marrow cells were
washed twice and resuspended with cold Ringer’s solution. Cells were lysed by
sonication and the protein concentration of crude extracts measured. Oxygen
measurements were performed at 37 ˚C in 0.4 ml samples containing Ringer’s
solution pH 7.4, 8.5 mg ml−1 bone marrow extracts, 1X regeneration system
(Thermo Scientiﬁc), 30 µM PQ metabolites, 30 µM NADP+. The assay mixture
without NADP+ was pre-incubated in the Oxytherm’s chamber at 37˚C while
recording oxygen content. Then, the reaction was initiated by addition of NADP+.
After 30, 10 µl of 5 mgml−1 catalase (prepared in 50 mM potassium phosphate
buffer pH 7.0) was added to release O2 from H2O2. Experiments with red blood
cells were performed as above with same amount of protein extracts.
Steady-state kinetic measurements. Kinetic measurements were determined
following Tsukamoto et al.37 and the assay conditions were optimised according to
Döhr et al.38 with minor modiﬁcations. Brieﬂy, huCPR kinetics of interaction with
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PQ and OH-PQm were measured as NADPH consumption via recording of
change in absorbance at 340 nm on a microplate spectrophotometer (Thermo
Electron Varioskan) at 25 °C. The activity assay of 0.3 ml contained 0.3 M potas-
sium phosphate (pH 7.7), 25 nM huCPR, 100 µM NADPH, and various con-
centrations of primaquine derivatives (0–200 µM 5-HPQ, 0–100 µM 5,6-DPQ,
0–150 µM PQQI, 0–150 µM 6OHPQQI, or 0–1000 µM PQ). Reactions were initi-
ated by adding NADPH to a ﬁnal concentration of 100 µM after equilibrating the
assay mixture with all other components at 25 °C for 2 min. Data were recorded
every 5 s over 4 min. The Michaelis–Menten equation was used to determine Km
and kcat values.
Statistics. Statistical analyses were done using GraphPad Prism version
5.04 and version 7 software (GraphPad Software, San Diego, California, USA,
www.graphpad.com). Signiﬁcance was calculated by two-tailed Mann Whitney
test. One-way or two-way ANOVA was used as appropriate. Extended statistics
tables for each analysis are provided as Additional Information.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying Figs. 1a, 2a–d, 6d, h and 7c and Supplementary Figs. 1a and
5d are provided as a Source Data ﬁle.
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